×
Abstract P6-06-02: Functional homologous recombination REpair CAPacity (RECAP) test in metastatic breast cancer biopsies
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-06-02

Jan 20th, 2019 - Introduction Tumors of germline BRCA1/2 mutated carriers cannot repair DNA double strand breaks (DSB) due to homologous recombination deficiency (HRD), rendering them highly sensitive to Poly ADP Ribose Polymerase (PARP) inhibitors and DSB inducing chemotherapy. Although evidence is emerging that the use of these therapies could be extended beyond germline BRCA1/2 mutated carriers, a robust val...

Abstract P2-10-02: Basal biomarkers nestin and INPP4b predict gemcitabine benefit in metastatic breast cancer: Results from the phase III SBG0102 clinical trial
http://cancerres.aacrjournals.org/content/78/4_Supplement/P2-10-02

Jul 4th, 2018 - Background: A growing body of evidence is suggesting that basal-like and triple negative breast cancers may be particularly sensitive to nucleoside analogues (gemcitabine, capecitabine). In a prospective-retrospective analysis of the phase III SBG0102 clinical trial randomizing metastatic breast cancer patients to gemcitabine plus docetaxel (GD) or to higher-dose single agent docetaxel (D), pat...

Abstract P4-09-12: Quantitative image features of nuclear and tubule architecture distinguish high and low oncotype DX risk categories of ductal carcinoma in situ from H&E tissue images
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-09-12

Jul 13th, 2018 - Background: Ductal Carcinoma in Situ (DCIS) is a pre-invasive stage of breast cancer, where malignant cells line the duct but have not spread into other parts of the breast. Oncotype DX (ODX) is a genomic test, which divide patients into three risk of recurrence categories (Low, Intermediate, and High) to help physicians determine if patients require adjuvant therapy. However, ODX is expensive,...

Abstract P4-03-12: Effects of PI3K inhibitors on endocrine-resistant cell lines and differences in the characteristics of ER positive breast cancer cells after acquired resistance to the inhibitors
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-03-12

Jan 25th, 2019 - Background Mutations in phosphatidylinositol 3-kinase (PI3K), which encodes the catalytic subunit of PI3Kα, is one of the most frequent genomic alterations and is found in about 40% of estrogen receptor (ER)-positive, HER2 negative breast cancers. PIK3CA mutations promote the growth and proliferation of cancers via activation of the PI3K/mammalian target of rapamycin pathway and can mediate res...

Abstract P4-08-04: The clinical utility of oncotype Dx for patients with recurrence scores of 10 or less: A value based pathology study of tumor histopathology and outcomes analysis in an integrate...
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-08-04

Jul 21st, 2018 - Introduction The majority of publications regarding breast cancer GEPTs rarely supply detailed breast tumor histopathology in their outcome studies. As a result, the cost effective role of clinical risk assessment with histopathology of breast carcinomas tends to be minimized. The aims of this study are to characterize the details of breast tumor histopathology of patients with Oncotype Dx Recu...

Abstract P3-13-06: Tailored neoadjuvant endocrine and chemo-endocrine therapy for postmenopausal patients with estrogen receptor-positive human epidermal growth factor receptor 2-negative primary b...
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-13-06

Oct 29th, 2018 - Aims We investigated the efficacy and safety of initial neoadjuvant endocrine therapy with exemestane (EXE) alone followed by subsequent tailored treatment with EXE alone for responders or EXE plus oral metronomic cyclophosphamide (CPA) for non-responders. Methods In this multicenter open-label phase II study, we enrolled postmenopausal patients with primary invasive estrogen receptor (ER)-posi...

Abstract P4-03-13: Combined estrogen receptor alpha and XPO1 targeting to overcome endocrine resistance
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-03-13

Jan 27th, 2019 - The majority of breast cancer-specific deaths occur in women with recurrent, ERα (+), metastatic tumors that are initially responsive to endocrine therapy yet become endocrine-resistant. There is a critical need for novel therapeutic approaches to re-sensitize recurrent ERα (+) tumors to endocrine therapies. The objective of this study was to elucidate mechanisms of improved effectiveness of co...

Abstract P1-06-02: Comparative survival analysis of multiparametric tests in the TEAM pathology study: What to do when molecular tests disagree?
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-06-02

Jul 29th, 2018 - Multiparametric assays for risk are increasingly used in the management of node-negative and node-positive hormone receptor-positive invasive breast cancer. Data from multiple sources suggests different tests may provide different risk estimates at the individual patient level1. Analysis from the TEAM pathology study (Bayani and Yao et al npjBreast Cancer, 2017) allows direct comparison of prog...

Abstract P4-03-10: Clinical observation of lapatinib versus continued use of trastuzumab for trastuzumab-resistant HER2-positive advanced breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-03-10

Jan 29th, 2019 - Objective: To compare the efficacy, adverse effects and survival of lapatinib versus continued use of trastuzumab for trastuzumab-resistant human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer. Methods: Patients who began the regimen of lapatinib plus capecitabine (LC or LX) or trastuzumab beyond progression (TBP) between May 2013 and October 2016 were selected from t...

Abstract P1-10-14: Abemaciclib tablet formulation is bioequivalent to capsules
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-10-14

Nov 1st, 2018 - Introduction: Abemaciclib is being developed for the treatment of cancer, including advanced and metastatic breast cancer. Tablet formulations, which are smaller than the capsules used in the pivotal MONARCH 1, 2 and 3 breast cancer studies, have recently been developed. This study evaluated the bioequivalence of abemaciclib capsule and tablet formulations following single 150-mg doses, and the...

Abstract P3-08-01: Prognostic performance of EndoPredict in invasive lobular carcinoma
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-08-01

Aug 12th, 2018 - Background: Invasive lobular carcinomas (ILC) account for around 15% of all oestrogen receptor (ER) positive invasive breast cancers. The EndoPredict assay (EPclin) is a multigene classifier to predict the likelihood of distant recurrence in ER-positive, HER2-negative breast cancer patients treated with adjuvant endocrine therapy and has been validated in several retrospective translational stu...

Abstract P1-10-06: A randomized phase II trial evaluating the endocrine activity and efficacy of neoadjuvant degarelix versus triptorelin in premenopausal patients receiving letrozole for primary e...
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-10-06

Nov 4th, 2018 - Background: Neoadjuvant endocrine therapy (NET) with gonadotropin-releasing hormone (GnRH) agonist and aromatase inhibitors is effective in selected premenopausal patients (pts). Degarelix, an antagonist of GnRH, has immediate onset of action through binding to GnRH receptors in the pituitary gland and thereby suppressing the production of LH and FSH. Its suppressing activity in premenopausal w...

Abstract P4-03-16: Cyclin E affects Smad3 pathway in trastuzumab resistant HER2+ breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-03-16

Feb 2nd, 2019 - Introduction and Objective: HER2 amplification is found in approximately 20% of patients with breast cancer and is associated with poor prognosis. Trastuzumab, a humanized anit-HER2 antibody, has been shown to improve patient outcomes, but clinical efficacy for this treatment is limited by the high rate of drug resistance. Cyclin E overexpression and cyclin-dependent kinase 2 (CDK2) activation ...

Abstract P3-08-11: The prognostic impact of retinoic acid-induced 2 (RAI2) expression in ERα-positive breast cancer patients
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-08-11

Aug 18th, 2018 - Background: Breast cancer cells disseminate to the bone marrow and form bone metastases in a large majority of late-stage patients. Retinoic Acid-Induced 2 (RAI2) was reported as a putative suppressor of early hematogenous dissemination of tumor cells to the bone marrow in breast cancer, particularly in estrogen receptor α (ERα)-positive breast cancer. Here, we investigated mRNA expression of R...

Abstract P3-08-02: Validation of the online prediction tool PREDICT v. 2.0: A large population-based study in the Netherlands
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-08-02

Aug 10th, 2018 - Background This study aimed to validate the online prediction tool PREDICT version 2.0 on a large population-based cohort in the Netherlands. Separate analyses were performed to study its validity in specific prognostic subgroups. Methods All women diagnosed with non-metastasised primary invasive breast cancer in 2005, who received surgery as part of their treatment, were selected from the nati...

Abstract P2-04-06: Changes of DNA methylation in the development of breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P2-04-06

Feb 5th, 2019 - Aberrant DNA methylation plays an important role in breast cancer initiation and progression via inactivation of tumor suppressor genes and activation of oncogenes. To better understand the changes of DNA methylation in the development of breast cancer, we analyzed genome-wide DNA methylation DNA data in breast tumor, adjacent normal tissue, and normal breast tissue from healthy women. Using th...

New Data on Androgen Receptor Blockade in Breast Cancer
https://www.practiceupdate.com/content/new-data-on-androgen-receptor-blockade-in-breast-cancer-a-review-from-sabcs-2017/61674/62

Dec 7th, 2017 - New Data on Androgen Receptor Blockade in Breast Cancer: A Review From SABCS 2017 Interview with Lee S. Schwartzberg MD, FACP Interview by Farzanna S Haffizulla MD, FACP, FAMWA

Abstract P3-07-01: IRS1 expression is required for estrogen stimulated growth in breast cancer cells
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-07-01

Mar 3rd, 2019 - Insulin receptor substrate (IRS) proteins are adaptor proteins phosphorylated by activated type I insulin-like growth factor receptor (IGF-1R) and insulin receptor (IR). In addition to their roles in normal cell physiology, we have shown IRS expression is required for breast cancer cell growth and motility. IRS1 plays a more important role in mitogenesis and survival while IRS2 in cancer cell m...

Radiation and Immunotherapy
https://www.practiceupdate.com/content/radiation-and-immunotherapy-novel-concepts-from-sabcs-2017/61677/62

Dec 10th, 2017 - Radiation and Immunotherapy: Novel Concepts From SABCS 2017 Interview with Lee S. Schwartzberg MD, FACP Interview by Farzanna S Haffizulla MD, FACP, FAMWA

Abstract P2-03-11: The immune microenvironment of HER2-positive ductal carcinoma in situ of the breast
http://cancerres.aacrjournals.org/content/78/4_Supplement/P2-03-11

Apr 11th, 2019 - Background: Ductal carcinoma in situ (DCIS) consists of a heterogeneous group of tumors that can be subclassified based on their molecular profile similar to invasive breast carcinomas. DCIS ducts are often surrounded by an inflammatory infiltrate, yet few studies have focused on this inflammatory response in the different subtypes of DCIS. The role of the immune microenvironment in tumor progr...